Co., Inc. (NYSE:MRK), recently purchased 2,832.861 shares of the company's common stock. The acquisition, valued at approximately $249,999, was completed at a price of $88.25 per share. Following this ...
Hosted on MSN9h
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Gynecologic oncologist Dr. John Wallbillich says people often don't have symptoms of cervical cancer, so it's important to ...
A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...
DES MOINES — State funding for the Double up Food Bucks Program, which provides a one-to-one match to Supplemental Nutrition ...
The bill proposes reversing a section in Iowa law that allows minors to personally consent to get the HPV vaccine without ...
During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback